Xen­tria and Meitheal ink li­cens­ing deal for rare lung dis­ease treat­ment in North Amer­i­ca

Xen­tria will li­cense its ex­per­i­men­tal pul­monary sar­coido­sis drug to Meitheal Phar­ma­ceu­ti­cals in a deal worth up to $680 mil­lion.

Meitheal spun out Xen­tria in 2020 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER